A detailed history of Lmr Partners LLP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Lmr Partners LLP holds 259,962 shares of BMY stock, worth $15.3 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
259,962
Holding current value
$15.3 Million
% of portfolio
0.12%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$39.66 - $51.75 $10.3 Million - $13.5 Million
259,962 New
259,962 $13.5 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $335,991 - $391,687
-6,265 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $370,700 - $434,227
6,265 New
6,265 $371,000
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $839,437 - $914,147
-13,559 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $254,805 - $286,581
-4,294 Reduced 24.05%
13,559 $856,000
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $86,436 - $97,948
-1,497 Reduced 7.74%
17,853 $1.11 Million
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $1.11 Million - $1.23 Million
19,350 New
19,350 $1.17 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $2.87 Million - $3.36 Million
-52,413 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $684,307 - $994,457
-14,748 Reduced 21.96%
52,413 $2.85 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $3.3 Million - $4.31 Million
67,161 New
67,161 $4.31 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $8.08 Million - $8.93 Million
-181,042 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $8.17 Million - $9.74 Million
181,042 New
181,042 $8.64 Million
Q4 2017

Jan 30, 2018

SELL
$59.94 - $65.35 $438,041 - $477,577
-7,308 Closed
0 $0
Q3 2017

Nov 09, 2017

BUY
$55.23 - $63.74 $403,620 - $465,811
7,308
7,308 $465,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.